Prolactinoma epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Prolactinoma}} | {{Prolactinoma}} | ||
{{CMG}} | {{CMG}} {{AE}}{{Faizan}} | ||
==Overview== | ==Overview== | ||
Revision as of 13:53, 3 September 2015
|
Prolactinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prolactinoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Prolactinoma epidemiology and demographics |
|
Risk calculators and risk factors for Prolactinoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
Autopsy studies indicate that 6-25% of the U. S. population have small pituitary tumors. Forty percent of these pituitary tumors produce prolactin, but most are not considered clinically significant. Clinically significant pituitary tumors affect the health of approximately 14 out of 100,000 people in United States.
Epidemiology and Demographics
Although small benign pituitary tumors are fairly common in the general population, symptomatic prolactinomas are uncommon. Prolactinomas occur more often in women than men and rarely occur in children.
Prevelance
Autopsy studies indicate that 6-25% of the U. S. population have small pituitary tumors. Forty percent of these pituitary tumors produce prolactin, but most are not considered clinically significant. Clinically significant pituitary tumors affect the health of approximately 14 out of 100,000 people in United States.
In nonselected surgical series, this tumor accounts for approximately 25-30% of all pituitary adenomas. Some growth hormone (GH)–producing tumors also co-secrete PRL. Microprolactinomas are much more common than macroprolactinomas